Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection

被引:47
作者
Jullien, V [1 ]
Tréluyer, JM [1 ]
Pons, G [1 ]
Rey, E [1 ]
机构
[1] Univ Paris 05, Serv Pharmacol Clin, Grp Hosp Cochin St Vincent de Paul, Assistance Publ Hop Paris, F-75674 Paris 14, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2003年 / 785卷 / 02期
关键词
tenofovir;
D O I
10.1016/S1570-0232(02)00933-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive high-performance liquid chromatography method was developed with spectrofluorimetric detection for the determination of tenofovir, a new HIV reverse transcriptase inhibitor, in human plasma. After precipitation of 200 mul of plasma samples by methanol and evaporation of the supernatant, fluorescent derivatized compounds were obtained by a 40-min incubation at 80 degreesC with chloroacetaldehyde 0.34% at pH 4.5. The assay, was performed isocratically using 5 mM Na2HPO4 (pH 6), containing tetrabutylammonium (TBA) chloride 5 mM, and acetonitrile (85:15, v/v) as mobile phase, and a Cluzeau C-8 plus satisfaction column maintained at 35 degreesC. Detection was performed at excitation and emission wavelengths set at 236 and 420 nm, respectively. In these conditions, tenofovir can be separated from adefovir, the internal standard, and endogenous substances. The method was found to be linear and has been validated over a concentration range of 5-1000 mug/l. The average coefficient of the limit of quantification (5 mug/l) was 5.38% and at this concentration, a signal-to-noise ratio of 500 was measured (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:377 / 381
页数:5
相关论文
共 5 条
[1]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[2]   Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults [J].
Deeks, SG ;
Barditch-Crovo, P ;
Lietman, PS ;
Hwang, F ;
Cundy, KC ;
Rooney, JF ;
Hellmann, NS ;
Safrin, S ;
Kahn, JO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2380-2384
[3]  
NAESENS L, 1992, CLIN CHEM, V38, P480
[4]   Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains [J].
Srinivas, RV ;
Fridland, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1484-1487
[5]  
Wainberg MA, 1999, ANTIVIR THER, V4, P87